BRPI1015916A2 - Molécula de ácido nucleico, vetor de expressão, célula hospedeira, bem como método para expressão de um construto de cadeia leve substituta (slc) ou de um polipeptídeo de slc - Google Patents

Molécula de ácido nucleico, vetor de expressão, célula hospedeira, bem como método para expressão de um construto de cadeia leve substituta (slc) ou de um polipeptídeo de slc

Info

Publication number
BRPI1015916A2
BRPI1015916A2 BRPI1015916-9A BRPI1015916A BRPI1015916A2 BR PI1015916 A2 BRPI1015916 A2 BR PI1015916A2 BR PI1015916 A BRPI1015916 A BR PI1015916A BR PI1015916 A2 BRPI1015916 A2 BR PI1015916A2
Authority
BR
Brazil
Prior art keywords
slc
expression
construct
nucleic acid
light chain
Prior art date
Application number
BRPI1015916-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Lawrence Horowitz
Ramesh Bhatt
Original Assignee
Sea Lane Biotechnologies Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sea Lane Biotechnologies Llc filed Critical Sea Lane Biotechnologies Llc
Publication of BRPI1015916A2 publication Critical patent/BRPI1015916A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Holo Graphy (AREA)
BRPI1015916-9A 2009-06-26 2010-06-25 Molécula de ácido nucleico, vetor de expressão, célula hospedeira, bem como método para expressão de um construto de cadeia leve substituta (slc) ou de um polipeptídeo de slc BRPI1015916A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22087809P 2009-06-26 2009-06-26
PCT/US2010/040052 WO2010151808A1 (en) 2009-06-26 2010-06-25 Expression of surrogate light chains

Publications (1)

Publication Number Publication Date
BRPI1015916A2 true BRPI1015916A2 (pt) 2015-09-01

Family

ID=42563044

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1015916-9A BRPI1015916A2 (pt) 2009-06-26 2010-06-25 Molécula de ácido nucleico, vetor de expressão, célula hospedeira, bem como método para expressão de um construto de cadeia leve substituta (slc) ou de um polipeptídeo de slc

Country Status (12)

Country Link
US (1) US8969082B2 (https=)
EP (2) EP3205723A1 (https=)
JP (2) JP2012531208A (https=)
KR (2) KR101829073B1 (https=)
CN (1) CN102498210B (https=)
AU (1) AU2010265949B2 (https=)
BR (1) BRPI1015916A2 (https=)
CA (1) CA2764729C (https=)
IL (1) IL216796A (https=)
MX (1) MX2012000129A (https=)
TW (1) TWI560271B (https=)
WO (1) WO2010151808A1 (https=)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101679974B (zh) 2007-03-27 2015-09-30 航道生物技术有限责任公司 包含抗体替代轻链序列的构建体和文库
CA2761681A1 (en) 2009-05-13 2010-11-18 Sea Lane Biotechnologies, Llc Neutralizing molecules to influenza viruses
DK3622815T3 (da) 2009-07-08 2023-06-26 Kymab Ltd Gnavermodeller og terapeutiske molekyler
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
AU2011283694B2 (en) 2010-07-29 2017-04-13 Xencor, Inc. Antibodies with modified isoelectric points
WO2013003647A2 (en) 2011-06-28 2013-01-03 Sea Lane Biotechnologies, Llc Multispecific stacked variable domain binding proteins
EP2736928B1 (en) 2011-07-28 2019-01-09 i2 Pharmaceuticals, Inc. Sur-binding proteins against erbb3
BR112014006394A2 (pt) 2011-09-19 2017-03-28 Kymab Ltd manipulação de diversidade genética de imunoglobulina e terapêuticos multi-anticorpos
WO2013045916A1 (en) * 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
US9975956B2 (en) 2011-12-22 2018-05-22 I2 Pharmaceuticals, Inc. Surrogate binding proteins which bind DR4 and/or DR5
WO2013109994A1 (en) 2012-01-20 2013-07-25 Sea Lane Biotechnologies, Llc Surrobody cojugates
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
KR102211837B1 (ko) 2013-01-14 2021-02-03 젠코어 인코포레이티드 신규한 이형이량체 단백질
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
WO2014113510A1 (en) 2013-01-15 2014-07-24 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
EP2970486B1 (en) 2013-03-15 2018-05-16 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US20150033372A1 (en) * 2013-05-01 2015-01-29 Kymab Limited Human VpreB & Chimaeric Surrogate Light Chains in Transgenic Non-Human Vertebrates
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
AU2014330922A1 (en) 2013-10-01 2016-03-03 Kymab Limited Animal models and therapeutic molecules
EP3699195A3 (en) 2014-03-28 2020-11-04 Xencor, Inc. Bispecific antibodies that bind to cd38 and cd3
EP3223907A2 (en) 2014-11-26 2017-10-04 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd38
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
PE20171324A1 (es) 2014-11-26 2017-09-11 Xencor Inc Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales
FI3240805T3 (fi) * 2014-12-15 2025-02-17 Univ California Cd19- ja cd20-vasteellinen bispesifinen tai-veräjän kimeerinen antigeenireseptori
EP3234120B1 (en) 2014-12-15 2025-09-03 The Regents of the University of California Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing
WO2016105450A2 (en) 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies
EP3253793A4 (en) * 2015-02-02 2018-11-14 i2 Pharmaceuticals, Inc. Anti-surrogate light chain antibodies
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
PL3368571T3 (pl) 2015-10-30 2023-05-02 The Regents Of The University Of California Polipeptydy odpowiadające na transformujący czynnik wzrostu beta i sposoby ich zastosowania
CA3007030A1 (en) 2015-12-07 2017-06-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and psma
JP7010854B2 (ja) 2016-06-14 2022-01-26 ゼンコア インコーポレイテッド 二重特異性チェックポイント阻害剤抗体
CN109715663B (zh) 2016-06-28 2022-11-25 Xencor股份有限公司 结合生长抑素受体2的异源二聚抗体
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
AU2017319702B2 (en) 2016-09-02 2024-11-14 The Regents Of The University Of California Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments
MY203000A (en) 2016-10-14 2024-06-01 Xencor Inc Il15/il15r� heterodimeric fc-fusion proteins
WO2019006472A1 (en) 2017-06-30 2019-01-03 Xencor, Inc. TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
JP2021502100A (ja) 2017-11-08 2021-01-28 ゼンコア インコーポレイテッド 新規抗ｐｄ−１配列を用いた二重特異性および単一特異性抗体
IL275426B2 (en) 2017-12-19 2025-03-01 Xencor Inc Engineered il-2 fc fusion proteins
CA3096052A1 (en) 2018-04-04 2019-10-10 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
EP3781598A1 (en) 2018-04-18 2021-02-24 Xencor, Inc. Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
SG11202010163QA (en) 2018-04-18 2020-11-27 Xencor Inc Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
AU2019355971B2 (en) 2018-10-03 2025-05-08 Xencor, Inc. IL-12 heterodimeric Fc-fusion proteins
CA3132185A1 (en) 2019-03-01 2020-09-10 Xencor, Inc. Heterodimeric antibodies that bind enpp3 and cd3
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
CA3192204A1 (en) 2020-08-19 2022-02-24 Xencor, Inc. Anti-cd28 and/or anti-b7h3 compositions
EP4294837A1 (en) 2021-02-16 2023-12-27 Children's Health Care d/b/a Children's Minnesota Methods for treating b-all by administering a pre-bcr complex antagonist
US11739144B2 (en) 2021-03-09 2023-08-29 Xencor, Inc. Heterodimeric antibodies that bind CD3 and CLDN6
EP4305065A1 (en) 2021-03-10 2024-01-17 Xencor, Inc. Heterodimeric antibodies that bind cd3 and gpc3

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
JPS60222842A (ja) 1984-04-19 1985-11-07 Fuji Photo Film Co Ltd ハロゲン化銀写真乳剤およびその製造方法
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
EP0269127B1 (en) 1986-11-27 1994-02-23 F. Hoffmann-La Roche Ag Nucleotide sequences which are selectively expressed in pre-B cells and probes therefor
US5182205A (en) 1986-11-27 1993-01-26 Hoffmann-La Roche Inc. Nucleotide sequences which are selectively expressed in pre-B cells and probes therefor
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5427908A (en) * 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
AU3725600A (en) 1999-03-02 2000-09-21 Maxygen, Inc. Surrogate orphan ligands for orphan receptors
US20030215453A1 (en) * 2002-05-14 2003-11-20 Dedera Douglas A. Methods of therapy and diagnosis using immunotargeting of cells expressing VpreB1 protein
AU2001245815A1 (en) 2000-03-15 2001-09-24 Incyte Genomics, Inc. Human immune response proteins
US20060147997A1 (en) * 2004-11-30 2006-07-06 Virosys Pharmaceuticals, Inc. PenetraBodies: receptor-mediated targeted delivery of functionally-active human antibody fragments into cytosol for the treatment of chronic infections and diseases
CN101679974B (zh) 2007-03-27 2015-09-30 航道生物技术有限责任公司 包含抗体替代轻链序列的构建体和文库
BRPI0915512A2 (pt) 2008-07-11 2017-06-20 Sea Lane Biotechnologies Llc construtos e bibliotecas compreendendo sequências substitutas de cadeia leve kappa de anticorpo

Also Published As

Publication number Publication date
TW201107468A (en) 2011-03-01
JP2016105714A (ja) 2016-06-16
TWI560271B (en) 2016-12-01
KR20180017231A (ko) 2018-02-20
AU2010265949B2 (en) 2016-05-05
CA2764729A1 (en) 2010-12-29
WO2010151808A1 (en) 2010-12-29
AU2010265949A1 (en) 2011-12-22
KR20120095343A (ko) 2012-08-28
EP2446032B8 (en) 2017-03-15
KR101829073B1 (ko) 2018-02-13
CA2764729C (en) 2019-04-02
IL216796A (en) 2015-09-24
CN102498210B (zh) 2015-07-29
EP2446032A1 (en) 2012-05-02
US8969082B2 (en) 2015-03-03
MX2012000129A (es) 2012-02-01
JP2012531208A (ja) 2012-12-10
US20100330676A1 (en) 2010-12-30
EP3205723A1 (en) 2017-08-16
CN102498210A (zh) 2012-06-13
EP2446032B1 (en) 2016-12-21
IL216796A0 (en) 2012-02-29

Similar Documents

Publication Publication Date Title
BRPI1015916A2 (pt) Molécula de ácido nucleico, vetor de expressão, célula hospedeira, bem como método para expressão de um construto de cadeia leve substituta (slc) ou de um polipeptídeo de slc
BR112012008173A2 (pt) molécula de ligação específica de rsv
BRPI0814781A2 (pt) Proteína, sequência de ácido nucleico, método para a produção de ácido itacônico, vetor, célula hospedeira, e, uso de um ácido cis-aconítico
AR113177A2 (es) Polipéptidos que tienen actividad de lisozima y polinucleótidos que los codifican
BR112012024287A2 (pt) anticorpo, composição farmacêutica, método, ácido nucleico, vetor de expressão e célula hospedeira
BRPI0911571A2 (pt) método para tratar um mamífero, análogo de insulina, ácido nucléico e célula hospedeira
BRPI0908303A2 (pt) Recuperação de ácidos orgânicos
HUE036684T2 (hu) Tisztított, módosított RNS-t tartalmazó RNS készítmények sejtek visszaprogramozásához
BRPI1011489A2 (pt) método para seleção de genes candidatos estatisticamente validados.
BRPI0922187A2 (pt) composição vetor, kit para a montagem de um polinucleotídeo, biblioteca de moléculas de ácido nucleico, métodos para gerar um polinucleotídeo, e uma célula hospedeira, célula hospedeira, polinucleotídeo, e , método para fabricar um vetor
BRPI1012204A2 (pt) método de pré-tratamento de biomassa para preparar bioetanol
DK2831241T3 (da) Kunstige nukleinsyremolekyler til forbedret protein- eller peptidekspression.
BRPI0821421A2 (pt) Sistema para o acionamento de, pelo menos, um flap de regulagem de um avião, bem como, um processo para o teste do sistema.
BR112014000627A2 (pt) polipepitídeo da polimerase mitante, proteína de fusão, moécula de ácido nucleico, vetor, processo de produção do vetor, célula hospedeira, método, composição, uso e kit
DE112009005162B8 (de) Steuerverfahren für ein Brennstoffzellensystem
DK2121908T3 (da) Nukleinsyremolekyler, der koder for trunkeret alternansucrase
BRPI0921823A2 (pt) produção de módulos de células solares
NO20085365A (no) Invertert indeks for kontekstuell søk
BR112013031810A2 (pt) valenceno sintase, ácido nucleico, vetor de expressão, anticorpo, célula hospedeira e métodos para preparar valenceno e nootkatona
BRPI1007427A2 (pt) processo de fabricação de um eletrolisador de alta temperatura ou de uma pilha a combustível de alta temperatura
BRPI1013484A8 (pt) protease, dna, vetor de expressão , célula transformada, e, método para produzir uma protease
BR112013014896A2 (pt) eletrodo para eletrólise, célula eletrólica, método de produção para um eletrodo para eletrólise
DK2701487T3 (da) Polynukleotider, der koder for enzymer fra jute-lignin- biosyntesevejen
BRPI0909004A2 (pt) Processo para produção de biogás
DK2611915T3 (da) Nukleinsyrefragmenter fra en ribosomal proteinpromoter til forstærkning af genekspression

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]